Clinical Trial Update: LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating the combination of panobinostat (LBH589) and bevacizumab in patients with recurrent malignant glioma; results we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Bevacizumab (bevacizumab)
• LBH589 (panobinostat)

Snippet

Sponsor: Patrick Y. Wen, MD | Conditions: Malignant Glioma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-11-28